-
Let’s Fix What’s Broken, without Breaking What’s Working
In this article by Dr. Bettina Hamelin of Innovative Medicines Canada, readers learn about the risks of replacing private drug plans with a limited national formulary and how that could […]
-
Waiting for New Medicines in Canada, Europe, and the United States
In this article by the Canadian Health Policy Institute, readers learn that Canadians wait far longer than patients in the U.S. or Europe to access newly approved medicines. Submission delays, […]
-
Health Canada to Modernize Biologic Drug Submission
In this article by Torys LLP, they explain an announcement from Health Canada that makes it easier and faster for new biologic and biosimilar medicines to be approved. The updated […]
-
•
Health and Life Sciences M&A in the Waiting Room as Tariff and Economic Uncertainty Grow
In this article by Zena Olijnyk for Lexpert, readers see how U.S. tariff threats and economic uncertainty are putting Canadian health and life sciences dealmaking on hold. Buyers and sellers […]
-
Pharmaceutical Industry Urges G7 to Prioritize Health Innovation as Global Strategic Pillar
In this article by IFPMA and Innovative Medicines Canada, they called on leaders to make health innovation a cornerstone of G7 policy. The open letter asked leaders to invest in […]
-
•
Trump Wants to Tariff Canadian-made Drugs
In this article from CBC News, they explain how proposed U.S. tariffs on Canadian-made medicines could disrupt cross-border supply chains, increase costs, and risk shortages of essential drugs. Experts warn […]
-
Patient Choice a Top Priority: Why Pharmacare Must Put Canadians First
Canada’s proposed pharmacare plan risks limiting patient choice by replacing effective, personalized treatments with a narrow one-size-fits-all formulary. Innovative Medicines Canada warns this could harm those with chronic or complex […]
-
Eight in 10 Doctors Concerned About Impact of Tariffs on Patients
In this article by the Canadian Medical Association, survey results show 88% of doctors worry about how tariffs will affect patients. Many of those surveyed cited rising costs of medications, […]
-
Life on Hold – How Canada’s Drug Approval Delays Endanger Patients
In this article by Nigel Rawson and John Adams for the Macdonald-Laurier Institute, they explore how Canada’s slow approval and reimbursement systems delay patient access to new medicines for years. […]
-
Canada Supports Biomanufacturing Capacity to Advance Next Generation Medicines
In March 2025, the Government of Canada announced a $62 million investment to build a 103,000-square-foot facility in Edmonton to scale up production of therapeutics and vaccines. The facility will […]
-
Government of Canada Invests in Southern Ontario’s Life Sciences Sector
In February 2025, the Government of Canada announced an over $16 million investment in six life sciences organizations in Southern Ontario to support research, commercial scale-up, and innovation infrastructure. The […]
-
•
Canada’s National Pharmacare Plan – Boon or Bane?
In this article by Nigel Rawson & John Adams, readers learn that with national pharmacare, Canada still faces serious barriers in approval, reimbursement, and government plan listings. The commentary warns […]
Category: Strengthening Canadian Life Sciences
Latest posts from our organization